Literature DB >> 9719964

Subclinical inflammation after laser in situ keratomileusis.

J J Pérez-Santonja1, H F Sakla, C Cardona, J M Ruiz-Moreno, J L Alió.   

Abstract

PURPOSE: To determine whether laser in situ keratomileusis (LASIK) for the correction of myopia induces an anterior chamber inflammatory response measurable with laser flare-cell photometry.
SETTING: Instituto Oftalmológico de Alicante, University of Alicante. Alicante, Spain.
METHODS: Twenty eyes in 20 patients had LASIK to correct myopia ranging from 2.50 to 15.00 diopters (D) (mean -8.94 +/- 3.25 [SD]). Anterior chamber inflammation was measured preoperatively and 1, 3, 7, and 15 days and 1 and 3 months postoperatively using the flare mode of a laser flare-cell meter. All eyes received topical fluorometholone 0.1% drops for 2 weeks postoperatively.
RESULTS: Anterior chamber flare values at 1 and 3 days and 1 week postoperatively were not significantly different from those found preoperatively. However, a significant decrease was found at 2 weeks and 1 month (P < .01 and P < .05, respectively). Flare values returned to their preoperative levels at 3 months. No significant correlations between postoperative flare values and depth of ablation were found.
CONCLUSION: In this study. LASIK did not induce an inflammatory response in the anterior chamber in the myopic eye.

Entities:  

Mesh:

Year:  1998        PMID: 9719964     DOI: 10.1016/s0886-3350(98)80098-9

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  2 in total

1.  Effect of Myopic Femtosecond Laser-Assisted LASIK on Anterior Chamber Inflammation (Flare Values) and Corneal Endothelium: A Prospective before and after Study.

Authors:  Kemal Turgay Özbilen; Emre Altinkurt; Nihan Aksu Ceylan; Gizem Sayar Bilgin; Nilüfer Gözüm
Journal:  J Ophthalmol       Date:  2021-11-26       Impact factor: 1.909

2.  Fibrinous anterior uveitis following laser in situ keratomileusis.

Authors:  Pragya Parmar; Amjad Salman; M Rajmohan; Nelson C A Jesudasan
Journal:  Indian J Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.